Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AMC Holdings is a biopharmaceutical company specializing in the research, development, and distribution of psychedelic-based medicinal products. The company is best known for its landmark exclusive partnership with the University of the West Indies (UWI) in Jamaica, which facilitates the cultivation, clinical research, and export of psilocybin and other psychedelic compounds. AMC Holdings focuses on creating standardized, pharmaceutical-grade formulations to address significant unmet needs in mental health, including major depressive disorder and PTSD. By leveraging Jamaica's unique regulatory environment for psychedelics, the company aims to bridge the gap between traditional botanical knowledge and modern clinical validation. Their operations encompass the entire value chain, from laboratory research and clinical trials to the global distribution of psychedelic medicines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AMC Holdings.